OrbiMed’s MALLINCKRODT PUBLIC LIMITED COMPANY MNK Stock Holding History

OrbiMed’s Portfolio MNK Stock Details MNK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-1,472,700	Closed	-$55M	–	151
2017 Q3	$55M	Hold	1,472,700	–	–	0.53%	58
2017 Q2	$66M	Hold	1,472,700	–	–	0.69%	46
2017 Q1	$65.6M	Hold	1,472,700	–	–	0.74%	43
2016 Q4	$73.4M	Buy	1,472,700 +302,500	+26%	+$17.8M	0.93%	36
2016 Q3	$81.7M	Sell	1,170,200 -138,800	-11%	-$10M	0.93%	42
2016 Q2	$79.6M	Hold	1,309,000	–	–	0.83%	42
2016 Q1	$80.2M	Buy	1,309,000 +47,000	+4%	+$3M	0.84%	38
2015 Q4	$94.2M	Buy	1,262,000 +89,000	+8%	+$5.99M	0.85%	37
2015 Q3	$75M	Buy	1,173,000 +378,000	+48%	+$37.4M	0.76%	40
2015 Q2	$93.6M	Buy	795,000 +3,999	+0.5%	+$493K	0.78%	39
2015 Q1	$100M	Buy	791,001 +224,000	+40%	+$25.6M	0.86%	37
2014 Q4	$56.1M	Buy	567,001 +273,000	+93%	+$25.1M	0.54%	44
2014 Q3	$26.5M	Buy	+294,001	New	+$23M	0.28%	64

Other funds holding MNK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

SCM

Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

OrbiMed's MNK Position: Q4 2017 in Review

OrbiMed sold out of MALLINCKRODT PUBLIC LIMITED COMPANY (MNK) in Q4 2017, closing a stake of 1,472,700 shares — an estimated $55M sold.

OrbiMed first reported a position in MNK in Q3 2014 and held it in 13 quarters. The position peaked at $100M in Q1 2015. 343 funds tracked by Wall St. Rank hold MNK as of Q4 2017.

OrbiMed reported no remaining MALLINCKRODT PUBLIC LIMITED COMPANY position as of Q4 2017 after selling out during the quarter.
OrbiMed sold 1,472,700 MALLINCKRODT PUBLIC LIMITED COMPANY shares in Q4 2017, an estimated $55M.
OrbiMed first reported a position in MALLINCKRODT PUBLIC LIMITED COMPANY in Q3 2014 and held it in 13 quarters.
OrbiMed's MALLINCKRODT PUBLIC LIMITED COMPANY position peaked at $100M in Q1 2015.
343 funds tracked by Wall St. Rank held MALLINCKRODT PUBLIC LIMITED COMPANY as of Q4 2017.

Based on OrbiMed's 13F filing for Q4 2017, filed 14 Feb 2018.